Adapthealth (AHCO)

Healthcare · Medical Devices
$6.06 -0.08% on the day Market cap $813M 52-week range $5.21 to $13.43 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
-19% a year for 10 years

At a market value of $813M, Adapthealth's free cash flow of $219M (fiscal 2025) would need to grow about -19% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 7 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Adapthealth's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price-18.6% a year
Free cash flow, last 7 years20.8% a year
Revenue, same period37.7% a year
Price to free cash flow3.7x

Fundamental grade

D

Five factors scored 1 to 9 from AHCO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation8
Profitability1
Growth2
Financial health2
Cash efficiency4

Results from SEC filings

Fiscal years, from Adapthealth's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$2.5B$3.0B$3.2B$3.3B$3.2B
Net income$156M$69M-$679M$90M-$71M
Free cash flow$72M-$18M$143M$236M$219M
EPS (diluted)$0.67$0.33-$5.31$0.61-$0.52
Operating margin9.2%6.4%-18.7%8.1%2.8%

Where the revenue comes from

Revenue by segments, fiscal 2025. Every breakdown, year by year.

Sleep Health$1.4B42%
Respiratory Health$691M21%
Diabetes Health$592M18%
Wellness at Home$583M18%

Superinvestors who own AHCO

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Trimmed $8M0.00%Q2 2026

Insider buying

Open-market purchases by Adapthealth's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.

DateInsiderSharesPriceValue
Mar 20, 2026 Richard M Cashin Jr
447,100$9.91$4M
Mar 19, 2026 Richard M Cashin Jr
727$9.94$7,226
Mar 12, 2026 Richard M Cashin Jr
689,336$9.73$7M
Mar 11, 2026 Richard M Cashin Jr
536,827$9.73$5M
Mar 10, 2026 Richard M Cashin Jr
820,528$9.73$8M

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when AHCO trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Adapthealth's stock price imply?

At a market value of $813M, Adapthealth would need its free cash flow to grow about -19% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 7 years its free cash flow grew 21% a year.

Are Adapthealth insiders buying the stock?

5 open-market insider purchases of AHCO in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Adapthealth?

1 of the superinvestors Investingly tracks hold AHCO in their latest 13F, including Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.